Floxuridine-induced sclerosing cholangitis: An ischemic cholangiopathy?
The DOI matches its Crossref record.
Abstract
A 43-year-old man underwent abdominoperineal resection of a rectal adenocarcinoma, and left hepatic lobectomy for a single metastasis. He then received hepatic artery infusions of floxuridine. The tumor did not recur, but sclerosing cholangitis and liver failure developed which necessitated orthotopic liver transplantation. In the hilus of the native liver, obstructive arteriopathy and portal venopathy were found. These lesions probably had been caused by drug-induced intravascular thrombosis. Thus, the sclerosing cholangitis that develops in many patients after floxuridine infusion may be ischemic rather than toxic. The patient described here is well, 14 months after orthotopic liver transplantation. Therefore, in some cases of floxuridine-induced cholangitis, liver transplantation appears to be indicated despite a history of metastasizing carcinoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
EASL Clinical Practice Guidelines: Drug-induced liver injury
Andrade, R. J., Aithal, G. P., Björnsson, E. S., Kaplowitz, N., Kullak-Ublick, G. A., Larrey, D., & Karlsen, T. H. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.02.014 · Cited by 1,276
Primary sclerosing cholangitis
Hirschfield, G. M., Karlsen, T. H., Lindor, K. D., & Adams, D. H. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60096-3 · Cited by 592
Primary Sclerosing Cholangitis
Lee, Y.-M., & Kaplan, M. M. (1995) · New England Journal of Medicine · doi:10.1056/nejm199504063321406 · Cited by 526
Liver Disease in Patients with Hereditary Hemorrhagic Telangiectasia
Garcia-Tsao, G., Korzenik, J. R., Young, L., Henderson, K. J., Jain, D., Byrd, B., Pollak, J. S., & White, R. I. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431305 · Cited by 402
Padda, M. S., Sanchez, M., Akhtar, A. J., & Boyer, J. L. (2011) · Hepatology · doi:10.1002/hep.24229 · Cited by 387
Sclerosing cholangitis: a focus on secondary causes
Abdalian, R., & Heathcote, J. E. (2006) · Hepatology · doi:10.1002/hep.21405 · Cited by 230
Drug-induced liver injury: Asia Pacific Association of Study of Liver consensus guidelines
Devarbhavi, H., Aithal, G., Treeprasertsuk, S., Takikawa, H., Mao, Y., Shasthry, S. M., Hamid, S., Tan, S. S., Philips, C. A., George, J., et al. (2021) · Hepatology International · doi:10.1007/s12072-021-10144-3 · Cited by 181
Vanishing bile duct syndrome in drug-induced liver disease
Desmet, V. J. (1997) · Journal of Hepatology · doi:10.1016/s0168-8278(97)82330-6 · Cited by 174
Portmann, B., & Zen, Y. (2012) · Histopathology · doi:10.1111/j.1365-2559.2011.03853.x · Cited by 70
Secondary sclerosing cholangitis in critically ill patients: current perspectives
Gudnason, H. O., & Björnsson, E. S. (2017) · Clinical and Experimental Gastroenterology · doi:10.2147/ceg.s115518 · Cited by 66
Nakanuma, Y., Zen, Y., & Portmann, B. C. (2012) · MacSween's Pathology of the Liver · doi:10.1016/b978-0-7020-3398-8.00010-6 · Cited by 56
Etiology and pathogenesis in primary sclerosing cholangitis
Boberg, K. M., Lundin, K. E. A., & Schrumpf, E. (1994) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365529409103625 · Cited by 53
Long-Term Outcomes After Drug-Induced Liver Injury
Hayashi, P. H., & Bjornsson, E. S. (2018) · Current Hepatology Reports · doi:10.1007/s11901-018-0411-0 · Cited by 26
Metadata
- Authors
- Ludwig, J., Kim, C. H., Wiesner, R. H., & Krom, R. A. F.
- Venue
- Hepatology
- Published
- 1989-02
- Volume
- 9
- Issue
- 2
- Pages
- 215-218
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W1995223983
- Cited by
- 156
- References
- 0
- FWCI
- 2.19
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.